Animal Research and Immunology Core

大湖区生物防御和新发传染病区域中心的使命 动物研究和免疫学核心(ARIC)是提供专业研究服务，以支持 针对NIAID A、B和C类病原体的疫苗、诊断和治疗方法的发展 在紧急情况下支持GLRCE，部署潮湿的实验室基础设施和生物防御 RCE网络的专业知识。在上一次筹资期间，南盟在 芝加哥大学和霍华德·泰勒·里基茨实验室(位于阿贡国家 实验室)，最先进的BSL-2/3和ABSL-2/3研究空间，使工作和科学培训成为可能 根据标准化的、安全的NIAID A-C类制剂实验室操作规范。收购的GLRCE ARIC CDC注册和认证以维持蓬勃发展的选择代理计划，该计划已经包括 几种不同的空调病原体：鼠疫杆菌(鼠疫)、炭疽杆菌(炭疽)、伤寒杆菌(斑疹伤寒)、立克次体(洛基) 山斑热)、地中海斑点热(R.conori)和耐药金黄色葡萄球菌(MRSA)。 ARIC使用基于网络的门户网站(www.glrce.org)进行广告宣传，并向用户提供研究服务 在研究界，包括动物模型、疫苗和免疫的毒力研究 反应研究、挑战实验、免疫反应的表征或 感染、免疫试剂和化验的制备、耐药性和治疗研究， 体外和体内微生物复制的测量，以及动物病理学研究。下一次 在资助期内，GLRCE ARIC建议提供标准化、高质量的动物模型系统，以 开发和维持空气生物学系统，以开发免疫学测试、试剂和相关的 免疫，并开发和维持小分子抑制剂的体外抗菌活性测试 NIAID A-C类特工。

The mission of the Great Lakes Regional Center for Biodefense and Emerging Infectious Diseases (GLRCE) Animal Research and Immunology Core (ARIC) is to provide professional research services in support of the development of vaccines, diagnostics and therapeutics against NIAID Category A, B and C agents and to support GLRCE under emergency situations, marshalling wet laboratory infrastructures and biodefense expertise for the RCE network. During the previous funding period, SARC established infrastructures at the University of Chicago and at the Howard Taylor Ricketts Laboratory (located at Argonne National Laboratory), state-of-the-art BSL-2/3 and ABSL-2/3 research space, enabling work and scientific training under standardized, safe laboratory practices on NIAID Category A-C agents. The GLRCE ARIC acquired CDC registration and certification to sustain a flourishing select agent program that already encompasses several different A-C agents: Y. pestis (plague), B. anthracis (anthrax), R. typhi (typhus), R. rickettsii (Rocky Mountain Spotted Fever), R. conori (Mediterranean Spotted Fever), and MRSA (drug resistant S. aureus). ARIC uses a web-based portal (www.glrce.org) to advertise and make research services available to users in the research community, which includes virulence studies in animal models, vaccine and immune responses studies, challenge experiments, characterization of immune responses to immunization or infection, preparation of immunological reagents and assays, drug resistance and therapy studies, measurements of microbial replication in vitro and in vivo, and animal pathology studies. For the next funding period, GLRCE ARIC proposes to provide standardized, high quality animal model systems, to develop and sustain aerobiology systems, to develop immunological tests, reagents and correlates of immunity, and to develop and sustain in vitro testing of small molecule inhibitors for antibiotic activity on NIAID category A-C agents.